In Vitro Antioxidant and Anti-Inflammatory Effects of Platelet-Rich Plasma Powder

富血小板血浆粉的体外抗氧化和抗炎作用

阅读:1

Abstract

BACKGROUND AND OBJECTIVE: Platelet-rich plasma (PRP) is emerging as a new treatment modality for inflammatory conditions, like osteoarthritis and ulcers, but no definitive mechanism has been established for this effect, and our study aims to explore the antioxidant and anti-inflammatory effects of the powder form of PRP on normal cells. MATERIALS AND METHODS: We used 3T3 fibroblast and RAW 264.7 macrophage cell lines, and all cells were pretreated with lipopolysaccharide (LPS), and diclofenac was used as a positive control for anti-inflammatory studies and ascorbic acid for antioxidant studies. We evaluated PRP's anti-inflammatory action on cell lines by checking cytokine levels (IL-1, IL-6, TNF-α, and MCP-1) and nitric oxide (NO) expression. Cytotoxicity on these cell lines was further evaluated by Hoechst and AO/EB staining. Antioxidant studies were carried out by studying reactive oxygen species (ROS) generation and by two chemical methods, 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay and ferric reducing power assay (FRAP) assay. RESULTS: In the DPPH assay, dose-dependent inhibition of DPPH was observed, while in the FRAP assay, absorbance values of optical activity were studied at 593 nm, and dose-dependent antioxidant activity was found compared to ascorbic acid. In cytotoxicity assays, PRP did not show any morphological damage. PRP exerted anti-inflammatory action in a dose-dependent manner (12.5, 25, and 50 µg) in ELISA-based cytokine assays (IL-1, IL-6, TNF-alpha, and MCP-1) and also ROS assays. CONCLUSION: PRP powder exerts anti-inflammatory and antioxidant effects on 3T3 and RAW cell lines. Further in vivo data are needed to generate the results and develop PRP powder as a therapeutic agent in various disorders.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。